Form 4: Intellia Therapeutics Executive Sells Shares to Cover Tax Obligations

David Lebwohl, EVP and Chief Medical Officer at Intellia Therapeutics, sold 9,557 shares of common stock to cover tax obligations related to vesting RSUs.

Summary

• David Lebwohl, the EVP and Chief Medical Officer of Intellia Therapeutics, sold 9,557 shares of the company's common stock on January 3, 2025.
• The sale was executed at a price of $12.18 per share.
• This transaction was a mandatory 'sell-to-cover' to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2025.
• The sale was not a volitional trade by Mr. Lebwohl.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, which is common in publicly traded companies. It does not indicate any change in the company's outlook or management's confidence.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice for executives receiving equity compensation in publicly traded companies.
• The number of shares sold is proportional to the tax obligations arising from the vesting of RSUs, which is a typical scenario.
• The price of $12.18 per share is the market price at the time of the transaction, which is consistent with standard practice.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the company's performance or outlook.

Key Dates

Keywords

Intellia Therapeutics, NTLA, insider trading, Form 4, stock sale, David Lebwohl, RSU, tax obligations, executive compensation